Cargando…

Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020

OBJECTIVES: To determine susceptibility to the novel β-lactam/ β-lactamase inhibitor combination imipenem/relebactam in clinical isolates recovered from intra-abdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream (BSI) infections in the SMART (Study for Monitoring Antimicrobial Resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Fernández, Sergio, Calvo, Jorge, Cercenado, Emilia, Suárez-Barrenechea, Ana Isabel, Fernández-Billón, María, Castillo, Francisco Javier, Gálvez-Benítez, Lydia, Tubau, Fe, Cerón, Ruth Esther Figueroa, Hernández-Cabezas, Alicia, Romo, Fernando González, Fariñas, María Carmen, Gómez, María, Díaz-Regañón, Jazmín, Cantón, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Quimioterapia 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238800/
https://www.ncbi.nlm.nih.gov/pubmed/36951688
http://dx.doi.org/10.37201/req/007.2023
_version_ 1785053358614118400
author García-Fernández, Sergio
Calvo, Jorge
Cercenado, Emilia
Suárez-Barrenechea, Ana Isabel
Fernández-Billón, María
Castillo, Francisco Javier
Gálvez-Benítez, Lydia
Tubau, Fe
Cerón, Ruth Esther Figueroa
Hernández-Cabezas, Alicia
Romo, Fernando González
Fariñas, María Carmen
Gómez, María
Díaz-Regañón, Jazmín
Cantón, Rafael
author_facet García-Fernández, Sergio
Calvo, Jorge
Cercenado, Emilia
Suárez-Barrenechea, Ana Isabel
Fernández-Billón, María
Castillo, Francisco Javier
Gálvez-Benítez, Lydia
Tubau, Fe
Cerón, Ruth Esther Figueroa
Hernández-Cabezas, Alicia
Romo, Fernando González
Fariñas, María Carmen
Gómez, María
Díaz-Regañón, Jazmín
Cantón, Rafael
author_sort García-Fernández, Sergio
collection PubMed
description OBJECTIVES: To determine susceptibility to the novel β-lactam/ β-lactamase inhibitor combination imipenem/relebactam in clinical isolates recovered from intra-abdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream (BSI) infections in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study in SPAIN during 2016 – 2020. METHODS: Broth microdilution MICs for imipenem/relebactam and comparators were determined by a central laboratory against isolates of Enterobacterales and Pseudomonas aeruginosa. MICs were interpreted using EUCAST-2021 breakpoints. RESULTS: In total, 5,210 Enterobacterales and 1,418 P. aeruginosa clinical isolates were analyzed. Imipenem/relebactam inhibited 98.8% of Enterobacterales. Distinguishing by source of infection susceptibility was 99.1% in BSI, 99.2% in IAI, 97.9% in RTI, and 99.2% in UTI. Of intensive care unit isolates (ICU) 97.4% were susceptible and of non-ICU isolates 99.2% were susceptible. In Enterobacterales, activity against Class A, Class B and Class D carbapenemases was 96.2%, 15.4% and 73.2%, respectively. In P. aeruginosa, imipenem/relebactam was active in 92.2% of isolates. By source of infection it was 94.8% in BSI, 92.9% in IAI, 91.7% in RTI, and 93.1% in UTI. An 88.7% of ICU isolates and 93.6% of non-ICU isolates were susceptible to imipenem/relebactam. Imipenem/relebactam remained active against P. aeruginosa ceftazidime-resistant (76.3%), cefepime-resistant (73.6%), imipenem-resistant (71.5%) and piperacillin-resistant (78.7%) isolates. Of all multidrug-resistant or difficult-to-treat resistance P. aeruginosa isolates, 75.1% and 46.2%, respectively, were susceptible to imipenem/relebactam. CONCLUSIONS: Imipenem/relebactam showed high rates of susceptibility in Enterobacterales and P. aeruginosa isolates from different sources of infection as well as depending on patients’ location (ICU or non-ICU scenarios).
format Online
Article
Text
id pubmed-10238800
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Sociedad Española de Quimioterapia
record_format MEDLINE/PubMed
spelling pubmed-102388002023-06-04 Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020 García-Fernández, Sergio Calvo, Jorge Cercenado, Emilia Suárez-Barrenechea, Ana Isabel Fernández-Billón, María Castillo, Francisco Javier Gálvez-Benítez, Lydia Tubau, Fe Cerón, Ruth Esther Figueroa Hernández-Cabezas, Alicia Romo, Fernando González Fariñas, María Carmen Gómez, María Díaz-Regañón, Jazmín Cantón, Rafael Rev Esp Quimioter Original OBJECTIVES: To determine susceptibility to the novel β-lactam/ β-lactamase inhibitor combination imipenem/relebactam in clinical isolates recovered from intra-abdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream (BSI) infections in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study in SPAIN during 2016 – 2020. METHODS: Broth microdilution MICs for imipenem/relebactam and comparators were determined by a central laboratory against isolates of Enterobacterales and Pseudomonas aeruginosa. MICs were interpreted using EUCAST-2021 breakpoints. RESULTS: In total, 5,210 Enterobacterales and 1,418 P. aeruginosa clinical isolates were analyzed. Imipenem/relebactam inhibited 98.8% of Enterobacterales. Distinguishing by source of infection susceptibility was 99.1% in BSI, 99.2% in IAI, 97.9% in RTI, and 99.2% in UTI. Of intensive care unit isolates (ICU) 97.4% were susceptible and of non-ICU isolates 99.2% were susceptible. In Enterobacterales, activity against Class A, Class B and Class D carbapenemases was 96.2%, 15.4% and 73.2%, respectively. In P. aeruginosa, imipenem/relebactam was active in 92.2% of isolates. By source of infection it was 94.8% in BSI, 92.9% in IAI, 91.7% in RTI, and 93.1% in UTI. An 88.7% of ICU isolates and 93.6% of non-ICU isolates were susceptible to imipenem/relebactam. Imipenem/relebactam remained active against P. aeruginosa ceftazidime-resistant (76.3%), cefepime-resistant (73.6%), imipenem-resistant (71.5%) and piperacillin-resistant (78.7%) isolates. Of all multidrug-resistant or difficult-to-treat resistance P. aeruginosa isolates, 75.1% and 46.2%, respectively, were susceptible to imipenem/relebactam. CONCLUSIONS: Imipenem/relebactam showed high rates of susceptibility in Enterobacterales and P. aeruginosa isolates from different sources of infection as well as depending on patients’ location (ICU or non-ICU scenarios). Sociedad Española de Quimioterapia 2023-03-22 2023 /pmc/articles/PMC10238800/ /pubmed/36951688 http://dx.doi.org/10.37201/req/007.2023 Text en © The Author 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
spellingShingle Original
García-Fernández, Sergio
Calvo, Jorge
Cercenado, Emilia
Suárez-Barrenechea, Ana Isabel
Fernández-Billón, María
Castillo, Francisco Javier
Gálvez-Benítez, Lydia
Tubau, Fe
Cerón, Ruth Esther Figueroa
Hernández-Cabezas, Alicia
Romo, Fernando González
Fariñas, María Carmen
Gómez, María
Díaz-Regañón, Jazmín
Cantón, Rafael
Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020
title Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020
title_full Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020
title_fullStr Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020
title_full_unstemmed Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020
title_short Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020
title_sort activity of imipenem/relebactam against enterobacterales and pseudomonas aeruginosa in spain. smart 2016-2020
topic Original
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238800/
https://www.ncbi.nlm.nih.gov/pubmed/36951688
http://dx.doi.org/10.37201/req/007.2023
work_keys_str_mv AT garciafernandezsergio activityofimipenemrelebactamagainstenterobacteralesandpseudomonasaeruginosainspainsmart20162020
AT calvojorge activityofimipenemrelebactamagainstenterobacteralesandpseudomonasaeruginosainspainsmart20162020
AT cercenadoemilia activityofimipenemrelebactamagainstenterobacteralesandpseudomonasaeruginosainspainsmart20162020
AT suarezbarrenecheaanaisabel activityofimipenemrelebactamagainstenterobacteralesandpseudomonasaeruginosainspainsmart20162020
AT fernandezbillonmaria activityofimipenemrelebactamagainstenterobacteralesandpseudomonasaeruginosainspainsmart20162020
AT castillofranciscojavier activityofimipenemrelebactamagainstenterobacteralesandpseudomonasaeruginosainspainsmart20162020
AT galvezbenitezlydia activityofimipenemrelebactamagainstenterobacteralesandpseudomonasaeruginosainspainsmart20162020
AT tubaufe activityofimipenemrelebactamagainstenterobacteralesandpseudomonasaeruginosainspainsmart20162020
AT ceronruthestherfigueroa activityofimipenemrelebactamagainstenterobacteralesandpseudomonasaeruginosainspainsmart20162020
AT hernandezcabezasalicia activityofimipenemrelebactamagainstenterobacteralesandpseudomonasaeruginosainspainsmart20162020
AT romofernandogonzalez activityofimipenemrelebactamagainstenterobacteralesandpseudomonasaeruginosainspainsmart20162020
AT farinasmariacarmen activityofimipenemrelebactamagainstenterobacteralesandpseudomonasaeruginosainspainsmart20162020
AT gomezmaria activityofimipenemrelebactamagainstenterobacteralesandpseudomonasaeruginosainspainsmart20162020
AT diazreganonjazmin activityofimipenemrelebactamagainstenterobacteralesandpseudomonasaeruginosainspainsmart20162020
AT cantonrafael activityofimipenemrelebactamagainstenterobacteralesandpseudomonasaeruginosainspainsmart20162020